Abstract
The novel pyrrolopyrimidine-based antifolate LY231514 (MTA), inhibits multiple folate-requiring enzymes including thymidylate synthase, glycinamide ribonucleotide formyltransferase and dihydrofolate reductase. Both thymidine and hypoxanthine are required to reverse MTA growth inhibition in leukaemia and colon cancer cells. Prevention of MTA growth inhibition by thymidine and/or hypoxanthine was investigated in two human lung (A549, COR L23) and two breast (MCF7, T47D) tumour cell lines, and the effect of the nucleoside/base transport inhibitor dipyridamole (DP) on thymidine and hypoxanthine rescue defined. MTA IC50values (continuous exposure three population doublings) were: A549–640 n M, COR L23–28 n M, MCF7–52 n M and T47D–46 n M. Thymidine (1 μM) completely prevented growth inhibition at the MTA IC50in all cell lines. At 10 × IC50, growth inhibition was only partially reversed by thymidine (≤ 10 μM); both thymidine and hypoxanthine (30 μM) being required for complete reversal, reflecting the multi-targeted nature of MTA. Growth inhibition by MTA was not affected by hypoxanthine alone. A non-toxic concentration (1 μM) of DP prevented thymidine/hypoxanthine rescue of MTA indicating that DP may potentiate MTA activity by preventing nucleoside and/or base salvage. Thymidine transport was inhibited by ≥ 89% by 1 μM DP in all cell lines, whereas hypoxanthine transport was inhibited only in A549 and MCF7 cells. Therefore, prevention of end-product reversal of MTA-induced growth inhibition by DP can be explained by inhibition of thymidine transport alone. © 2000 Cancer Research Campaign
Similar content being viewed by others
Article PDF
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Calvert AH and Walling JM (1998) Clinical studies with MTA. Br J Cancer 78: 35–40
Chan TCK and Howell SB (1990) Role of hypoxanthine and thymidine in determining methotrexate plus dipyridamole cytotoxicity. Eur J Cancer 26: 907–911
Chen TR (1977) In situ detection of mycoplasma contamination in cell cultures by fluorescent Hoechst 33258 stain. Exp Cell Res 104: 255–262
Curtin NJ and Harris AL (1988) Potentiation of quinazoline antifolate (CB3717) toxicity by dipyridamole in human lung carcinoma, A549, cells. Biochem Pharmacol 37: 2213–2120
Curtin NJ, Newell DR and Harris AL (1989) Modulation of dipyridamole action by α1acid glycoprotein: reduced potentiation of quinazoline antifolate (CB3717) cytotoxicity by dipyridamole. Biochem Pharmacol 38: 3281–3288
Curtin NJ, Harris AL and Aherne GW (1991) Mechanism of cell death following thymidylate synthase inhibition: 2′-deoxyuridine-5′-triphosphate accumulation, DNA damage, and growth inhibition following exposure to CB3717 and dipyridamole. Cancer Res 51: 2346–2352
Howell SB, Mansfield SJ and Taetle R (1981) Significance of variation in serum thymidine concentration for the marrow toxicity of methotrexate. Cancer Chemother Pharmacol 5: 221–226
Hughes JM and Tattersall MHN (1989) Potentiation of methotrexate lymphocytotoxicity in vitro by inhibitors of nucleoside transport. Br J Cancer 59: 381–384
Jackman AL, Taylor GA, Gibson W, Kimbell R, Brown M, Calvert AH, Judson IR and Hughes LR (1991) ICI D1694, a quinazoline antifolate thymidylate synthase inhibitor that is a potent inhibitor of L1210 tumour cell growth in vitro and in vivo: a new agent for clinical study. Cancer Res 51: 5579–5586
Kinsella AR and Haran MS (1991) Decreasing sensitivity to cytotoxic agents parallels increasing tumorigenicity in human fibroblasts. Cancer Res 51: 1855–1859
Kremer JMH, Wilting J and Janssen LHM (1988) Drug binding to human alpha-1-acid glycoprotein in health and disease. Pharmacol Rev 40: 1–47
Mahoney C, Wolfram KM, Cocetto DM and Bjornsson TD (1982) Dipyridamole kinetics. Clin Pharmacol Ther 31: 330–338
Marshman E, Newell DR, Calvert AH, Dickinson AM, Patel HRH, Campbell FC and Curtin NJ (1998) Dipyridamole potentiates antipurine antifolate activity in the presence of hypoxanthine in tumour cells but not in normal tissues in vitro. Clin Cancer Res 11: 2895–2902
Nelson JA and Drake S (1984) Potentiation of methotrexate toxicity by dipyridamole. Cancer Res 44: 2493–2496
Paterson ARP, Kolassa N and Cass CE (1981) Transport of nucleoside drugs in animal cells. Pharmacol Ther 12: 515–536
Plagemann PGW and Wohlhueter RM (1984 a) Hypoxanthine transport in mammalian cells: cell type-specific differences in sensitivity to inhibition by dipyridamole and uridine. J Membrane Biol 81: 255–262
Plagemann PGW and Wohlhueter RM (1984 b) Nucleoside transport in cultured mammalian cells: multiple forms with different sensitivity to inhibition by nitrobenzylthioinosine or hypoxanthine. Biochim Biophys Acta 773: 39–52
Shih C, Chen VJ, Gossett LS, Gates SB, MacKeller WC, Habeck LL, Shackelford KA, Mendelsohn LG, Soose DJ, Patel VF, Andis SL, Bewley JR, Rayl EA, Moroson BA, Beardsley GP, Kohler W, Ratnam M and Schultz RM (1997) LY231514, a pyrrolo[2,3-d]pyrimidine-based antifolate that inhibits multiple folate-requiring enzymes. Cancer Res 57: 1116–1123
Taylor GA, Jackman AL, Calvert AH and Harrap KR (1984) Plasma nucleoside and base levels following treatment with the new thymidylate synthase inhibitor CB3717. Purine Metabolism in Man IV 165B: 379–382
Traut TW (1994) Physiological concentrations of purines and pyrimidines. Mol Cell Biochem 140: 1–22
Turner RN, Aherne GW and Curtin NJ (1997) Selective potentiation of lomotrexol growth inhibition by dipyridamole through cell-specific inhibition of hypoxanthine salvage. Br J Cancer 76: 1300–1307
Van Mouwerik TJ, Pangallo CA, Willson JKV and Fischer PH (1987) Augmentation of methotrexate cytotoxicity in human colon cancer cells achieved through inhibition of thymidine salvage by dipyridamole. Biochem Pharmacol 36: 809–814
Wadler S, Subar M, Green MD, Wiernik PH and Muggia FM (1987) Phase II trial of oral methotrexate and dipyridamole in colorectal carcinoma. Cancer Treat Rep 71: 821–824
Ward WHJ, Kimbell R and Jackman AL (1992) Kinetic characteristics of ICI D1694: a quinazoline antifolate which inhibits thymidylate synthase. Biochem Pharmacol 43: 2029–2031
Weber G (1983) Biochemical strategy of cancer cells and the design of chemotherapy: GHA Clowes Memorial Lecture. Cancer Res 43: 3466–3492
Wilson JKV, Fischer PH, Remick SC, Tutsch KD, Grem JL, Nieting L, Alberti D, Bruggink J and Trump DL (1989) Methotrexate and dipyridamole combination chemotherapy based upon inhibition of nucleoside salvage in humans. Cancer Res 49: 1866–1870
Wolhueter RM, Graff JC and Plagemann PGW (1978) A rapid-mixing technique to measure transport in suspended animal cells: applications to nucleoside transport in Novikoff rat hepatoma cells. Methods Cell Biol 20: 211–236
Wung WE and Howell SB (1984) Hypoxanthine concentrations in normal subjects and patients with solid tumours and leukaemia. Cancer Res 44: 3144–3148
Author information
Authors and Affiliations
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Smith, P., Marshman, E., Newell, D. et al. Dipyridamole potentiates the in vitro activity of MTA (LY231514) by inhibition of thymidine transport. Br J Cancer 82, 924–930 (2000). https://doi.org/10.1054/bjoc.1999.1020
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1054/bjoc.1999.1020
Keywords
This article is cited by
-
Enhanced anticancer activity of combined treatment of imatinib and dipyridamole in solid Ehrlich carcinoma-bearing mice
Naunyn-Schmiedeberg's Archives of Pharmacology (2020)
-
An evaluation of thymidine phosphorylase as a means of preventing thymidine rescue from the thymidylate synthase inhibitor raltitrexed
Cancer Chemotherapy and Pharmacology (2006)